Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
February 28 2024 - 8:30AM
Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading
radiopharmaceutical-focused company committed to enabling
clinicians to Find, Fight and Follow disease to deliver better
patient outcomes, today announced the promotion of Amanda
Morgan to Chief Commercial Officer and her elevation to be a
member of the company’s Executive Team, effective March 25, 2024.
In her role, Ms. Morgan will continue to lead the Company’s
commercial strategy and activities, including Sales, Marketing,
Market Access, Commercial Operations, and Customer
Experience. Ms. Morgan has served as the Company’s Senior Vice
President of Commercial since November 2022. She will continue to
report to Paul Blanchfield, Lantheus’ President.
“Amanda has led our commercial efforts to grow the PSMA PET
imaging market and solidify PYLARIFY as the agent of choice in an
increasingly competitive market,” said Paul Blanchfield. “She has
also worked effectively to lead our annual business planning
process and ensure we have the focus, talent, and culture to remain
the leading radiopharmaceutical-focused company. I am confident in
her capacity to guide our commercial activities, ensuring ongoing
value generation for patients, customers, and shareholders.”
With over 20 years of experience in the healthcare industry, Ms.
Morgan is a seasoned commercial leader. Prior to joining Lantheus,
she was Chief Revenue and Customer Officer at Acadia
Pharmaceuticals, where she successfully led the commercial
organization. Prior to her tenure at Acadia, Ms. Morgan held
progressively challenging roles at Shire Plc, including U.S. Head
of Sales and U.S. Head of Patient Services, supporting
multi-billion-dollar pharmaceutical businesses. Ms. Morgan holds a
Bachelor of Business Administration from The University of
Iowa.
"I am honored and excited to step into the role of Chief
Commercial Officer at Lantheus," said Ms. Morgan. "Being a part of
this incredible company, with its history of groundbreaking science
and dedication to leadership in competitive markets, has been a
rewarding journey. I am eager to deepen my collaboration with our
talented team, building upon our collective success and advancing
Lantheus' diverse portfolio of products, always with a primary
focus on enhancing patient well-being."
About Lantheus Lantheus is the
leading radiopharmaceutical-focused company, delivering
life-changing science to enable clinicians to Find, Fight and
Follow disease to deliver better patient outcomes. Headquartered
in Massachusetts with offices in New
Jersey, Canada and Sweden, Lantheus has
been providing radiopharmaceutical solutions for more than 65
years. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary
StatementsThis press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, that are subject to risks and
uncertainties and are made pursuant to the safe harbor provisions
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may be identified by their use of terms
such as “continue,” “execute,” “will” and other similar terms. Such
forward-looking statements are based upon current plans, estimates
and expectations that are subject to risks and uncertainties that
could cause actual results to materially differ from those
described in the forward-looking statements. The inclusion of
forward-looking statements should not be regarded as a
representation that such plans, estimates and expectations will be
achieved. Readers are cautioned not to place undue reliance on the
forward-looking statements contained herein, which speak only as of
the date hereof. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by law. Risks and uncertainties that could cause our
actual results to materially differ from those described in the
forward-looking statements are discussed in our filings with the
Securities and Exchange Commission (including those described in
the Risk Factors section in our Annual Reports on Form 10-K and our
Quarterly Reports on Form 10-Q).
Contacts:
LantheusMark KinarneyVice President, Investor
Relations978-671-8842ir@lantheus.com
Melissa DownsSenior Director, External
Communications646-975-2533media@lantheus.com
Lantheus (NASDAQ:LNTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lantheus (NASDAQ:LNTH)
Historical Stock Chart
From Apr 2023 to Apr 2024